KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Gains from Sales and Divestitures (2017 - 2023)

Historic Gains from Sales and Divestitures for Biolife Solutions (BLFS) over the last 7 years, with Q1 2023 value amounting to $346184.0.

  • Biolife Solutions' Gains from Sales and Divestitures rose 5859.63% to $346184.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $346184.0, marking a year-over-year increase of 5859.63%. This contributed to the annual value of $569535.0 for FY2022, which is 5047.08% up from last year.
  • According to the latest figures from Q1 2023, Biolife Solutions' Gains from Sales and Divestitures is $346184.0, which was up 5859.63% from $569535.0 recorded in Q4 2022.
  • Biolife Solutions' 5-year Gains from Sales and Divestitures high stood at $569535.0 for Q4 2022, and its period low was $53026.0 during Q1 2020.
  • Its 5-year average for Gains from Sales and Divestitures is $236073.8, with a median of $224774.0 in 2021.
  • As far as peak fluctuations go, Biolife Solutions' Gains from Sales and Divestitures soared by 33614.08% in 2021, and later tumbled by 561.6% in 2022.
  • Quarter analysis of 5 years shows Biolife Solutions' Gains from Sales and Divestitures stood at $125818.0 in 2019, then skyrocketed by 66.0% to $208858.0 in 2020, then surged by 81.22% to $378502.0 in 2021, then skyrocketed by 50.47% to $569535.0 in 2022, then plummeted by 39.22% to $346184.0 in 2023.
  • Its Gains from Sales and Divestitures stands at $346184.0 for Q1 2023, versus $569535.0 for Q4 2022 and $448056.0 for Q3 2022.